OS Therapies (OSTX) Income from Continuing Operations (2023 - 2026)
OS Therapies' (OSTX) quarterly Income from Continuing Operations came in at 10321487.0 in Q1 2026, down 106.45% YoY from 159931592.54 in Q1 2025, and up 23.32% on a QoQ basis from 13460833.0 in Q4 2025.
OS Therapies (OSTX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Income from Continuing Operations data on file, last reported at 10321487.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 106.45% year-over-year to 10321487.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36444762.0 (down 193.76% YoY) and the FY2025 annual result came in at 30178447.0, down 97.05% from the prior year.
- Income from Continuing Operations rose to 10321487.0 in Q1 2026, from 13460833.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1464566.0 in Q4 2023 to a low of 13460833.0 in Q4 2025.
- A 4-year average of 4489300.85 and a median of 2875232.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 37.83% — and 2025, when it sank 352.62%.
- Tracing OSTX's Income from Continuing Operations over 4 years: stood at 1464566.0 in 2023, then slumped by 103.06% to 2973980.0 in 2024, then slumped by 352.62% to 13460833.0 in 2025, then grew by 23.32% to 10321487.0 in 2026.
- The last three Income from Continuing Operations figures came in at 10321487.0 (Q1 2026), 13460833.0 (Q4 2025), and 7376502.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | -8.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.32 Mn |
| Dec 31, 2025 | -13.46 Mn |
| Sep 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -5.29 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | -2.97 Mn |
| Sep 30, 2024 | -2.88 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -1.72 Mn |
| Dec 31, 2023 | -1.46 Mn |
| Sep 30, 2023 | -1.97 Mn |
| Jun 30, 2023 | -2.51 Mn |
| Mar 31, 2023 | -1.85 Mn |